Traders Sell Gilead Sciences, Inc. (GILD) on Strength (GILD)
Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Thursday. $263.80 million flowed into the stock on the tick-up and $343.83 million flowed out of the stock on the tick-down, for a money net flow of $80.03 million out of the stock. Of all companies tracked, Gilead Sciences had the 11th highest net out-flow for the day. Gilead Sciences traded up $1.58 for the day and closed at $81.59
GILD has been the subject of a number of recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price for the company. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, August 29th. Berenberg Bank set a $86.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Finally, Leerink Swann reaffirmed a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and an average target price of $85.64.
The company has a market capitalization of $106.55 billion, a PE ratio of 8.86 and a beta of 1.14. The stock has a 50-day moving average of $82.69 and a 200-day moving average of $72.48.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the company earned $3.08 EPS. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.55%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $83.05, for a total value of $2,076,250.00. Following the sale, the executive vice president now owns 101,488 shares of the company’s stock, valued at $8,428,578.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. 1.30% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in GILD. Waldron LP lifted its position in shares of Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 1,752 shares during the last quarter. Conning Inc. increased its holdings in Gilead Sciences by 241.0% in the 1st quarter. Conning Inc. now owns 120,564 shares of the biopharmaceutical company’s stock worth $8,189,000 after purchasing an additional 85,212 shares in the last quarter. Dowling & Yahnke LLC increased its holdings in Gilead Sciences by 1.0% in the 1st quarter. Dowling & Yahnke LLC now owns 48,601 shares of the biopharmaceutical company’s stock worth $3,301,000 after purchasing an additional 492 shares in the last quarter. HealthInvest Partners AB increased its holdings in Gilead Sciences by 3.5% in the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock worth $7,947,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD increased its holdings in Gilead Sciences by 9.7% in the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 109,223 shares of the biopharmaceutical company’s stock worth $7,418,000 after purchasing an additional 9,654 shares in the last quarter. Institutional investors and hedge funds own 73.97% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/19/traders-sell-gilead-sciences-inc-gild-on-strength-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.